Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 106

1.

Utility of TERT Promoter Mutations for Cutaneous Primary Melanoma Diagnosis.

Thomas NE, Edmiston SN, Tsai YS, Parker JS, Googe PB, Busam KJ, Scott GA, Zedek DC, Parrish EA, Hao H, Slater NA, Pearlstein MV, Frank JS, Kuan PF, Ollila DW, Conway K.

Am J Dermatopathol. 2018 Sep 11. doi: 10.1097/DAD.0000000000001259. [Epub ahead of print]

PMID:
30211730
2.

The Changing Paradigms for Breast Cancer Surgery: Performing Fewer and Less-Invasive Operations.

Ollila DW, Hwang ES, Brenin DR, Kuerer HM, Yao K, Feldman S.

Ann Surg Oncol. 2018 Oct;25(10):2807-2812. doi: 10.1245/s10434-018-6618-z. Epub 2018 Jul 2.

PMID:
29968033
3.

Inherited Genetic Variants Associated with Melanoma BRAF/NRAS Subtypes.

Thomas NE, Edmiston SN, Orlow I, Kanetsky PA, Luo L, Gibbs DC, Parrish EA, Hao H, Busam KJ, Armstrong BK, Kricker A, Cust AE, Anton-Culver H, Gruber SB, Gallagher RP, Zanetti R, Rosso S, Sacchetto L, Dwyer T, Ollila DW, Begg CB, Berwick M, Conway K; GEM Study Group.

J Invest Dermatol. 2018 Nov;138(11):2398-2404. doi: 10.1016/j.jid.2018.04.025. Epub 2018 May 9.

4.

Suppression of TGFβ-mediated conversion of endothelial cells and fibroblasts into cancer associated (myo)fibroblasts via HDAC inhibition.

Kim DJ, Dunleavey JM, Xiao L, Ollila DW, Troester MA, Otey CA, Li W, Barker TH, Dudley AC.

Br J Cancer. 2018 May;118(10):1359-1368. doi: 10.1038/s41416-018-0072-3. Epub 2018 Apr 26.

PMID:
29695769
5.

Ductal Carcinoma In Situ Simultaneously Involving the Breast and Epithelial Inclusions in an Ipsilateral Axillary Lymph Node.

Commander LA, Ollila DW, O'Connor SM, Hertel JD, Calhoun BC.

Int J Surg Pathol. 2018 Sep;26(6):564-568. doi: 10.1177/1066896918763899. Epub 2018 Mar 21.

PMID:
29560779
6.

Implementing a Program of Talimogene laherparepvec.

Collichio F, Burke L, Proctor A, Wallack D, Collichio A, Long PK, Ollila DW.

Ann Surg Oncol. 2018 Jul;25(7):1828-1835. doi: 10.1245/s10434-018-6361-5. Epub 2018 Feb 7.

PMID:
29417403
7.

Tumor Mitotic Rate and Association with Recurrence in Sentinel Lymph Node Negative Stage II Melanoma Patients.

Laks S, Meyers MO, Deal AM, Frank JS, Stitzenberg KB, Yeh JJ, Thomas NE, Ollila DW.

Am Surg. 2017 Sep 1;83(9):972-978.

PMID:
28958277
8.

Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial.

Giuliano AE, Ballman KV, McCall L, Beitsch PD, Brennan MB, Kelemen PR, Ollila DW, Hansen NM, Whitworth PW, Blumencranz PW, Leitch AM, Saha S, Hunt KK, Morrow M.

JAMA. 2017 Sep 12;318(10):918-926. doi: 10.1001/jama.2017.11470.

9.

Associations of MC1R Genotype and Patient Phenotypes with BRAF and NRAS Mutations in Melanoma.

Thomas NE, Edmiston SN, Kanetsky PA, Busam KJ, Kricker A, Armstrong BK, Cust AE, Anton-Culver H, Gruber SB, Luo L, Orlow I, Reiner AS, Gallagher RP, Zanetti R, Rosso S, Sacchetto L, Dwyer T, Parrish EA, Hao H, Gibbs DC, Frank JS, Ollila DW, Begg CB, Berwick M, Conway K; GEM Study Group.

J Invest Dermatol. 2017 Dec;137(12):2588-2598. doi: 10.1016/j.jid.2017.07.832. Epub 2017 Aug 24.

PMID:
28842324
10.

Association of Incident Amelanotic Melanoma With Phenotypic Characteristics, MC1R Status, and Prior Amelanotic Melanoma.

Vernali S, Waxweiler WT, Dillon PM, Kanetsky PA, Orlow I, Luo L, Busam KJ, Kricker A, Armstrong BK, Anton-Culver H, Gruber SB, Gallagher RP, Zanetti R, Rosso S, Sacchetto L, Dwyer T, Cust AE, Ollila DW, Begg CB, Berwick M, Thomas NE; GEM Study Group.

JAMA Dermatol. 2017 Oct 1;153(10):1026-1031. doi: 10.1001/jamadermatol.2017.2444.

11.

Functional melanoma-risk variant IRF4 rs12203592 associated with Breslow thickness: a pooled international study of primary melanomas.

Gibbs DC, Ward SV, Orlow I, Cadby G, Kanetsky PA, Luo L, Busam KJ, Kricker A, Armstrong BK, Cust AE, Anton-Culver H, Gallagher RP, Zanetti R, Rosso S, Sacchetto L, Ollila DW, Begg CB, Berwick M, Thomas NE; GEM Study Group.

Br J Dermatol. 2017 Nov;177(5):e180-e182. doi: 10.1111/bjd.15784. Epub 2017 Oct 6. No abstract available.

12.

Patient Symptoms Are the Most Frequent Indicators of Recurrence in Patients with American Joint Committee on Cancer Stage II Melanoma.

Berger AC, Ollila DW, Christopher A, Kairys JC, Mastrangelo MJ, Feeney K, Dabbish N, Leiby B, Frank JA, Stitzenberg KB, Meyers MO.

J Am Coll Surg. 2017 Apr;224(4):652-659. doi: 10.1016/j.jamcollsurg.2016.12.038. Epub 2017 Feb 8.

PMID:
28189663
13.

Axillary Management of Stage II/III Breast Cancer in Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-Positive) and CALGB 40603 (Triple-Negative).

Ollila DW, Cirrincione CT, Berry DA, Carey LA, Sikov WM, Hudis CA, Winer EP, Golshan M.

J Am Coll Surg. 2017 Apr;224(4):688-694. doi: 10.1016/j.jamcollsurg.2016.12.036. Epub 2017 Jan 13.

14.

Cancer Risk after Fat Transfer: A Multicenter Case-Cohort Study.

Myckatyn TM, Wagner IJ, Mehrara BJ, Crosby MA, Park JE, Qaqish BF, Moore DT, Busch EL, Silva AK, Kaur S, Ollila DW, Lee CN.

Plast Reconstr Surg. 2017 Jan;139(1):11-18. doi: 10.1097/PRS.0000000000002838.

15.

Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II-III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance).

Golshan M, Cirrincione CT, Sikov WM, Carey LA, Berry DA, Overmoyer B, Henry NL, Somlo G, Port E, Burstein HJ, Hudis C, Winer E, Ollila DW; Alliance for Clinical Trials in Oncology.

Breast Cancer Res Treat. 2016 Nov;160(2):297-304. Epub 2016 Oct 4.

16.

Metastasectomy for Stage IV Melanoma in the Era of Effective Systemic Agents.

Ollila DW, Lopez NE, Hsueh EC.

Crit Rev Oncog. 2016;21(1-2):37-55. doi: 10.1615/CritRevOncog.2016014729. Review.

PMID:
27481001
17.

Breast Conservation Therapy Versus Mastectomy: Shared Decision-Making Strategies and Overcoming Decisional Conflicts in Your Patients.

Margenthaler JA, Ollila DW.

Ann Surg Oncol. 2016 Oct;23(10):3133-7. doi: 10.1245/s10434-016-5369-y. Epub 2016 Jul 27.

PMID:
27464606
18.

Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma.

Andtbacka RH, Agarwala SS, Ollila DW, Hallmeyer S, Milhem M, Amatruda T, Nemunaitis JJ, Harrington KJ, Chen L, Shilkrut M, Ross M, Kaufman HL.

Head Neck. 2016 Dec;38(12):1752-1758. doi: 10.1002/hed.24522. Epub 2016 Jul 13.

19.

How successful is NST in increasing breast-conserving surgery rates in TNBC patients?

Ollila DW, Golshan M, Boughey JC.

Bull Am Coll Surg. 2016 Apr;101(4):40-2. No abstract available.

PMID:
27337767
20.

Patterns of Local-Regional Management Following Neoadjuvant Chemotherapy in Breast Cancer: Results From ACOSOG Z1071 (Alliance).

Haffty BG, McCall LM, Ballman KV, McLaughlin S, Jagsi R, Ollila DW, Hunt KK, Buchholz TA, Boughey JC.

Int J Radiat Oncol Biol Phys. 2016 Mar 1;94(3):493-502. doi: 10.1016/j.ijrobp.2015.11.005. Epub 2015 Nov 10.

21.

Association of Interferon Regulatory Factor-4 Polymorphism rs12203592 With Divergent Melanoma Pathways.

Gibbs DC, Orlow I, Bramson JI, Kanetsky PA, Luo L, Kricker A, Armstrong BK, Anton-Culver H, Gruber SB, Marrett LD, Gallagher RP, Zanetti R, Rosso S, Dwyer T, Sharma A, La Pilla E, From L, Busam KJ, Cust AE, Ollila DW, Begg CB, Berwick M, Thomas NE; GEM Study Group.

J Natl Cancer Inst. 2016 Feb 8;108(7). pii: djw004. doi: 10.1093/jnci/djw004. Print 2016 Jul.

22.

How Informed Is the Decision About Breast Reconstruction After Mastectomy?: A Prospective, Cross-sectional Study.

Lee CN, Ubel PA, Deal AM, Blizard LB, Sepucha KR, Ollila DW, Pignone MP.

Ann Surg. 2016 Dec;264(6):1103-1109.

23.

Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib.

Carey LA, Berry DA, Cirrincione CT, Barry WT, Pitcher BN, Harris LN, Ollila DW, Krop IE, Henry NL, Weckstein DJ, Anders CK, Singh B, Hoadley KA, Iglesia M, Cheang MC, Perou CM, Winer EP, Hudis CA.

J Clin Oncol. 2016 Feb 20;34(6):542-9. doi: 10.1200/JCO.2015.62.1268. Epub 2015 Nov 2.

24.

Impact of neoadjuvant chemotherapy in stage II-III triple negative breast cancer on eligibility for breast-conserving surgery and breast conservation rates: surgical results from CALGB 40603 (Alliance).

Golshan M, Cirrincione CT, Sikov WM, Berry DA, Jasinski S, Weisberg TF, Somlo G, Hudis C, Winer E, Ollila DW; Alliance for Clinical Trials in Oncology.

Ann Surg. 2015 Sep;262(3):434-9; discussion 438-9. doi: 10.1097/SLA.0000000000001417.

25.

Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma.

Thomas NE, Edmiston SN, Alexander A, Groben PA, Parrish E, Kricker A, Armstrong BK, Anton-Culver H, Gruber SB, From L, Busam KJ, Hao H, Orlow I, Kanetsky PA, Luo L, Reiner AS, Paine S, Frank JS, Bramson JI, Marrett LD, Gallagher RP, Zanetti R, Rosso S, Dwyer T, Cust AE, Ollila DW, Begg CB, Berwick M, Conway K; GEM Study Group.

JAMA Oncol. 2015 Jun;1(3):359-68. Erratum in: JAMA Oncol. 2015 Jun;1(3):285.

26.

IL2 Inducible T-cell Kinase, a Novel Therapeutic Target in Melanoma.

Carson CC, Moschos SJ, Edmiston SN, Darr DB, Nikolaishvili-Feinberg N, Groben PA, Zhou X, Kuan PF, Pandey S, Chan KT, Jordan JL, Hao H, Frank JS, Hopkinson DA, Gibbs DC, Alldredge VD, Parrish E, Hanna SC, Berkowitz P, Rubenstein DS, Miller CR, Bear JE, Ollila DW, Sharpless NE, Conway K, Thomas NE.

Clin Cancer Res. 2015 May 1;21(9):2167-76. doi: 10.1158/1078-0432.CCR-14-1826.

27.

Inherited genetic variants associated with occurrence of multiple primary melanoma.

Gibbs DC, Orlow I, Kanetsky PA, Luo L, Kricker A, Armstrong BK, Anton-Culver H, Gruber SB, Marrett LD, Gallagher RP, Zanetti R, Rosso S, Dwyer T, Sharma A, La Pilla E, From L, Busam KJ, Cust AE, Ollila DW, Begg CB, Berwick M, Thomas NE; GEM Study Group.

Cancer Epidemiol Biomarkers Prev. 2015 Jun;24(6):992-7. doi: 10.1158/1055-9965.EPI-14-1426. Epub 2015 Apr 2.

28.

Prognostic significance of tumor mitotic rate in T2 melanoma staged with sentinel lymphadenectomy.

Baker JJ, Meyers MO, Deal AM, Frank JF, Stitzenberg KB, Ollila DW.

J Surg Oncol. 2015 May;111(6):711-5. doi: 10.1002/jso.23880. Epub 2015 Feb 8.

PMID:
25663414
29.

Vascular channels formed by subpopulations of PECAM1+ melanoma cells.

Dunleavey JM, Xiao L, Thompson J, Kim MM, Shields JM, Shelton SE, Irvin DM, Brings VE, Ollila DW, Brekken RA, Dayton PA, Melero-Martin JM, Dudley AC.

Nat Commun. 2014 Oct 22;5:5200. doi: 10.1038/ncomms6200.

30.

Another brick in the wall: toward a better understanding of melanoma of unknown primary.

Ollila DW, Meyers MO.

Ann Surg Oncol. 2014 Dec;21(13):4054-5. doi: 10.1245/s10434-014-4027-5. No abstract available.

PMID:
25201497
31.

Comparison of clinicopathologic features and survival of histopathologically amelanotic and pigmented melanomas: a population-based study.

Thomas NE, Kricker A, Waxweiler WT, Dillon PM, Busman KJ, From L, Groben PA, Armstrong BK, Anton-Culver H, Gruber SB, Marrett LD, Gallagher RP, Zanetti R, Rosso S, Dwyer T, Venn A, Kanetsky PA, Orlow I, Paine S, Ollila DW, Reiner AS, Luo L, Hao H, Frank JS, Begg CB, Berwick M; Genes, Environment, and Melanoma (GEM) Study Group.

JAMA Dermatol. 2014 Dec;150(12):1306-314.

32.

Systematic review: surgery for patients with metastatic melanoma during active treatment with ipilimumab.

Baker JJ, Stitzenberg KB, Collichio FA, Meyers MO, Ollila DW.

Am Surg. 2014 Aug;80(8):805-10. Review.

PMID:
25105403
33.

DNA methylation profiles in primary cutaneous melanomas are associated with clinically significant pathologic features.

Thomas NE, Slater NA, Edmiston SN, Zhou X, Kuan PF, Groben PA, Carson CC, Hao H, Parrish E, Moschos SJ, Berwick M, Ollila DW, Conway K.

Pigment Cell Melanoma Res. 2014 Nov;27(6):1097-105. doi: 10.1111/pcmr.12289. Epub 2014 Jul 14.

34.

Validation of the VE1 immunostain for the BRAF V600E mutation in melanoma.

Pearlstein MV, Zedek DC, Ollila DW, Treece A, Gulley ML, Groben PA, Thomas NE.

J Cutan Pathol. 2014 Sep;41(9):724-32. doi: 10.1111/cup.12364. Epub 2014 Jul 4.

35.

Local recurrence rates are low in high-risk neoadjuvant breast cancer in the I-SPY 1 Trial (CALGB 150007/150012; ACRIN 6657).

Cureton EL, Yau C, Alvarado MD, Krontiras H, Ollila DW, Ewing CA, Monnier S, Esserman LJ.

Ann Surg Oncol. 2014 Sep;21(9):2889-96. doi: 10.1245/s10434-014-3721-7. Epub 2014 May 1.

36.

Routine restaging PET/CT and detection of initial recurrence in sentinel lymph node positive stage III melanoma.

Baker JJ, Meyers MO, Frank J, Amos KD, Stitzenberg KB, Ollila DW.

Am J Surg. 2014 Apr;207(4):549-54. doi: 10.1016/j.amjsurg.2013.04.012.

PMID:
24674829
37.

Tumor-infiltrating lymphocyte grade in primary melanomas is independently associated with melanoma-specific survival in the population-based genes, environment and melanoma study.

Thomas NE, Busam KJ, From L, Kricker A, Armstrong BK, Anton-Culver H, Gruber SB, Gallagher RP, Zanetti R, Rosso S, Dwyer T, Venn A, Kanetsky PA, Groben PA, Hao H, Orlow I, Reiner AS, Luo L, Paine S, Ollila DW, Wilcox H, Begg CB, Berwick M.

J Clin Oncol. 2013 Nov 20;31(33):4252-9. doi: 10.1200/JCO.2013.51.3002. Epub 2013 Oct 14.

38.

Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial.

Boughey JC, Suman VJ, Mittendorf EA, Ahrendt GM, Wilke LG, Taback B, Leitch AM, Kuerer HM, Bowling M, Flippo-Morton TS, Byrd DR, Ollila DW, Julian TB, McLaughlin SA, McCall L, Symmans WF, Le-Petross HT, Haffty BG, Buchholz TA, Nelson H, Hunt KK; Alliance for Clinical Trials in Oncology.

JAMA. 2013 Oct 9;310(14):1455-61. doi: 10.1001/jama.2013.278932.

39.

Phase 2 study of pre-excision single-dose intraoperative radiation therapy for early-stage breast cancers: six-year update with application of the ASTRO accelerated partial breast irradiation consensus statement criteria.

Vanderwalde NA, Jones EL, Kimple RJ, Moore DT, Klauber-Demore N, Sartor CI, Ollila DW.

Cancer. 2013 May 1;119(9):1736-43. doi: 10.1002/cncr.27915. Epub 2013 Jan 29.

40.

Breast surgeon's survey: no consensus for surgical treatment of pleomorphic lobular carcinoma in situ.

Blair SL, Emerson DK, Kulkarni S, Hwang ES, Malcarne V, Ollila DW.

Breast J. 2013 Jan-Feb;19(1):116-8. doi: 10.1111/tbj.12062. Epub 2012 Dec 10. No abstract available.

PMID:
23231019
41.

Phase I study and biomarker analysis of lapatinib and concurrent radiation for locally advanced breast cancer.

Kimple RJ, Horton JK, Livasy CA, Shields JM, Lawrence JA, Chiu WM, Ivanova A, Ollila DW, Carey LA, Halle JS, Sartor CI, Dees EC.

Oncologist. 2012;17(12):1496-503. doi: 10.1634/theoncologist.2012-0256. Epub 2012 Sep 24.

42.

Relative value unit impact of complex skin closures to academic surgical melanoma practices.

Khandelwal CM, Meyers MO, Yeh JJ, Amos KD, Frank JS, Long P, Ollila DW.

Am J Surg. 2012 Sep;204(3):327-31. doi: 10.1016/j.amjsurg.2011.10.014.

PMID:
22920403
43.

Early recurrence in sentinel lymph node positive stage III melanoma patients.

Baker JJ, Ollila DW, Deal AM, Frank J, Amos KD, Meyers MO.

Am Surg. 2012 Jul;78(7):808-13.

PMID:
22748543
44.

LKB1/STK11 inactivation leads to expansion of a prometastatic tumor subpopulation in melanoma.

Liu W, Monahan KB, Pfefferle AD, Shimamura T, Sorrentino J, Chan KT, Roadcap DW, Ollila DW, Thomas NE, Castrillon DH, Miller CR, Perou CM, Wong KK, Bear JE, Sharpless NE.

Cancer Cell. 2012 Jun 12;21(6):751-64. doi: 10.1016/j.ccr.2012.03.048.

45.

Decision making about surgery for early-stage breast cancer.

Lee CN, Chang Y, Adimorah N, Belkora JK, Moy B, Partridge AH, Ollila DW, Sepucha KR.

J Am Coll Surg. 2012 Jan;214(1):1-10. doi: 10.1016/j.jamcollsurg.2011.09.017. Epub 2011 Nov 6.

46.

Optimum excision margins for melanoma.

Thompson JF, Ollila DW.

Lancet. 2011 Nov 5;378(9803):1608-10. doi: 10.1016/S0140-6736(11)61615-2. Epub 2011 Oct 23. No abstract available.

PMID:
22027548
47.

Rationale for complete metastasectomy in patients with stage IV metastatic melanoma.

Ollila DW, Gleisner AL, Hsueh EC.

J Surg Oncol. 2011 Sep;104(4):420-4. doi: 10.1002/jso.21961. Review.

PMID:
21858837
48.

A phase 2 trial of complete resection for stage IV melanoma: results of Southwest Oncology Group Clinical Trial S9430.

Ollila DW.

Cancer. 2011 Oct 15;117(20):4579-81. doi: 10.1002/cncr.26118. Epub 2011 Mar 31. No abstract available.

49.

Impact of breast cancer molecular subtypes on locoregional recurrence in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer.

Meyers MO, Klauber-Demore N, Ollila DW, Amos KD, Moore DT, Drobish AA, Burrows EM, Dees EC, Carey LA.

Ann Surg Oncol. 2011 Oct;18(10):2851-7. doi: 10.1245/s10434-011-1665-8. Epub 2011 Mar 26.

PMID:
21442348
50.

Local control following single-dose intraoperative radiotherapy prior to surgical excision of early-stage breast cancer.

Kimple RJ, Klauber-DeMore N, Kuzmiak CM, Pavic D, Lian J, Livasy CA, Chiu WM, Moore DT, Sartor CI, Ollila DW.

Ann Surg Oncol. 2011 Apr;18(4):939-45. doi: 10.1245/s10434-010-1392-6.

PMID:
21061074

Supplemental Content

Loading ...
Support Center